11 registrations that name dulaglutide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 11 registrations
Status
Phase
61US sites across 28 states
1
2 to 4
5 to 19
20 or more
All 11 registrations
RecruitingNCT06739122
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Phase 3
Eli Lilly and Company
About 55 people
Started Jan 10, 2025
In plain words A Phase 3 study of dulaglutide in people 10 to 17, run by Eli Lilly and Company. It plans to enroll about 55 people at 51 sites, 41 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 17. Conditions: Type 2 Diabetes.
Have Type 2 diabetes treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to screening.
Have a body weight ≥50 kilograms (kg) and Body Mass Index (BMI) of >85th percentile
The exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide
Registered summary
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Where, as registered
41 US sites in 26 states; also Argentina (5), Mexico (5).
RecruitingNCT07668336
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Phase 3
Eli Lilly and Company
About 170 people
Started Jul 8, 2026
In plain words A Phase 3 study of dulaglutide in people 10 to 17, run by Eli Lilly and Company. It plans to enroll about 170 people at 71 sites, 17 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 17. Conditions: Diabetes Mellitus, Type 2.
Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
Have HbA1c > 6.5% to ≤ 11.0% at screening
Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile
The exclusion criteria are on the listing.
What it tests, as registered
Orforglipron; Dulaglutide
Registered summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
Where, as registered
17 US sites in 10 states; also Japan (11), India (8), Brazil (7), Italy (7), Mexico (5), South Korea (5), Belgium (3), Spain (3), United Kingdom (3), Taiwan (2).
RecruitingNCT04731272
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Phase 2
University of Pennsylvania
About 30 people
Started Jul 16, 2021
In plain words A Phase 2 study of dulaglutide in people 18 and older, run by University of Pennsylvania. It plans to enroll about 30 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cystic Fibrosis; Pancreatic Insufficiency; Abnormal Glucose Tolerance; Diabetes.
1\. Male or female, aged ≥18 years on date of consent
2\. Confirmed diagnosis of CF, defined by positive sweat test or Cystic Fibrosis transmembrane conductance regulator (CFTR) mutation analysis according to Cystic Fibrosis Foundation (CFF) diagnostic criteria.
3\. Pancreatic insufficiency defined by clinical requirement for pancreatic enzyme replacement.
4\. Abnormal glucose tolerance defined by OGTT criteria for EGI, IGT, or CFRD, or diagnosed CFRD.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Registered summary
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT05478707
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Phase 2
AdventHealth Translational Research Institute
About 47 people
Started Oct 5, 2023
In plain words A Phase 2 study of dulaglutide in people 18 to 40, run by AdventHealth Translational Research Institute. It plans to enroll about 47 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Diabetes Mellitus, Type 1; Endothelial Dysfunction.
History of type 1 diabetes, duration > 5 years
Age 18-40 years
HbA1c < 8.5%
BMI 19-34.9 kg/m2
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide; Placebo
Registered summary
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Where, as registered
1 US site in 1 state.
RecruitingNCT06324461
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Phase 4
The University of Hong Kong
About 372 people
Started Mar 20, 2024
In plain words A Phase 4 study of dulaglutide in people 18 and older, run by The University of Hong Kong. It plans to enroll about 372 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Myocardial Injury.
Age ≥ 18 years
Planned elective intermediate to high risk non-cardiac surgery
Anticipated to remain hospitalized for at least one night after surgery
Voluntarily agrees to participate by providing written informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide 0.75mg subcutaneous injection
Registered summary
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. The full summary is on the listing.
Where, as registered
No US site; China (3).
RecruitingNCT07309094
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Observational
Cardenal Herrera University
About 250 people
Started Sep 15, 2023
In plain words An observational study of dulaglutide in people 18 to 90, run by Cardenal Herrera University. It plans to enroll about 250 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2.
> or = 18 years of age
diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis
had uncontrolled T2DM, CVDs and/or obesity
willing to participate in the study and sign informed consent
The exclusion criteria are on the listing.
What it tests, as registered
GLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs
Registered summary
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT07109700
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
In plain words A Phase 2 study of dulaglutide in people 18 to 65, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It plans to enroll about 216 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Type 2 Diabetes.
Confirmed as Type 2 Diabetes Mellitus (T2DM) for at least 24 weeks;
Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5%
Body Mass Index (BMI within the range of 22.5 ~ 40.0 kg/m2
This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic (PK) characteristics of HDM1005 in subjects with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control after diet/exercise or metformin therapy. A total of 216 subjects will be enrolled. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07282041
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
Phase 2 and 3
National University of Singapore
About 130 people
Started Dec 17, 2025
In plain words A Phase 2 and 3 study of dulaglutide in people 21 to 80, run by National University of Singapore. It plans to enroll about 130 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 80. Conditions: Intracranial Atherosclerosis; Stroke, Ischemic.
Adult patients aged 21 - 80 years old inclusive,
Able to provide consent,
Score 3 or less on the Modified Rankin Score (mRS),
Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA
The exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide
Registered summary
One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA). The full summary is on the listing.
Where, as registered
No US site; Singapore (1).
Not yet recruitingNCT07156539
A Phase 3 Study of HS-20094 in Patients With T2DM
Phase 3
Jiangsu Hansoh Pharmaceutical Co., Ltd.
About 546 people
Starts Sep 30, 2025 (estimated)
In plain words A Phase 3 study of dulaglutide in people 18 and older, run by Jiangsu Hansoh Pharmaceutical Co., Ltd.. It plans to enroll about 546 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Type 2 Diabetes.
Males and females, Age ≥18 years at the time of signing informed consent.
Stable daily dose(s) for ≥90 days prior to screening of : 1) Any metformin formulations ≥1500 mg daily or maximum tolerated (≥1000mg daily).
Glycated hemoglobin was 7.5% ≤HbA1c ≤11.0%;
BMI ≥ 23 kg/m2.
The exclusion criteria are on the listing.
What it tests, as registered
HS-20094 Injection; Dulaglutide Injection
Registered summary
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.
Where, as registered
No US site; China (2).
Not yet recruitingNCT07537088
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
Phase 4
First Affiliated Hospital of Wannan Medical College
About 468 people
Starts May 2026 (estimated)
In plain words A Phase 4 study of dulaglutide in people 18 and older, run by First Affiliated Hospital of Wannan Medical College. It plans to enroll about 468 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease.
1.Patients aged ≥18 years with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)
2.Hemoglobin A1c (HbA1c) 7.0%-11%
3.Urine albumin-to-creatinine ratio (UACR) 300-5000 mg/g
4.Body mass index (BMI) 21-45 kg/m²
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dulaglutide; SGLT2i; Finerenone
Registered summary
The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07677891
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus
Phase 2
ProGen. Co., Ltd.
About 60 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of dulaglutide in people 19 to 75, run by ProGen. Co., Ltd.. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 75. Conditions: Type 2 Diabetes.
Adults aged 19 to 75 years who provide informed consent.
Diagnosed with type 2 diabetes for at least 6 months prior to screening.
Stable on dulaglutide therapy (0.75 or 1.5 mg) for at least 12 weeks prior to screening, with dose and dosing interval maintained unchanged for 8 weeks prior to enrollment.
HbA1c ≤ 7.5% at screening.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
PG-102(MG12); Dulaglutide
Registered summary
This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy. The treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.